CJ Wiedermann has authored a new paper on DIC/sepsis. As Wiedermann is the author of another paper that GTC considers important support for the DIC/sepsis program, this new paper ought to be worth reading for anyone here who is fluent in German.
>> Endogenous Anticoagulant Therapy for Sepsis: Success and Failure
Internist (Berl). 2007 Mar 28;
[Article in German]
Wiedermann CJ.
Abteilung fur Innere Medizin, Zentralkrankenhaus und Akademisches Lehrkrankenhaus der Medizinischen Universitat Innsbruck in Bozen, L.-Bohler-Strasse 5, 39100, Bozen, Italien
Whereas antithrombin and tifacogin [the NVS drug that used to be owned by Chiron] failed to improve clinical outcome in cases of severe sepsis, drotrecogin alfa (activated) [Xigris] increased the chances of survival of patients with this condition. Concerns about efficacy and safety of drotrecogin alfa have been raised because of internal and external validity and internal consistency problems found in the PROWESS study, and because of the drug's single positive pivotal phase III documentation that led to restricted marketing authorisations for only a subgroup of studied patients whose randomisation had not been stratified. Concerns intensified with data from ADDRESS, the PROWESS follow-up, and pediatric studies.
It is difficult to make rational and safe recommendations for drotrecogin alfa use on the available evidence. Further trials have been suggested. The relevant bodies should review product approval in light of their own guidelines for marketing authorisations on the basis of single pivotal trials and request the further study required to prevent the possibility of patients receiving a non-efficacious and potentially lethal drug. <<
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.